Psyence Biomedical Ltd(PBM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PBM Psyence Biomedical Ltd

Pre-Mkt 01-21 09:18:11 EST

0.6700

+0.0000

0.00%

盘前0.7500

+0.0800+11.94%

09:17 EST

High0.6700	Low0.6700	Vol0.00
Open0.6700	D1 Closing0.6700	Amplitude0.00%
Mkt Cap4.28M	Tradable Cap4.06M	Total Shares6.39M
T/O0.00	T/O Rate0.00%	Tradable Shares6.07M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PBM","market":"US","secType":"STK","nameCN":"Psyence Biomedical Ltd","latestPrice":0.67,"timestamp":1768942800000,"preClose":0.67,"halted":0,"volume":0,"hourTrading":{"tag":"盘前","latestPrice":0.75,"preClose":0.67,"latestTime":"09:17 EST","volume":60129,"amount":50250.36630357,"timestamp":1769005040181,"change":0.08,"changeRate":0.119403,"amplitude":0.462687},"delay":0,"changeRate":0,"floatShares":6067100,"shares":6388600,"eps":-2.105,"marketStatus":"Pre-Mkt","change":0,"latestTime":"01-21 09:18:11 EST","open":0.67,"high":0.67,"low":0.67,"amount":0,"amplitude":0,"askPrice":0.8192,"askSize":500,"bidPrice":0.7502,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-2.105,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769005800000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.67,"preHourTrading":{"tag":"盘前","latestPrice":0.75,"preClose":0.67,"latestTime":"09:17 EST","volume":60129,"amount":50250.36630357,"timestamp":1769005040181,"change":0.08,"changeRate":0.119403,"amplitude":0.462687},"volumeRatio":0.22317759807831294},"requestUrl":"/m/hq/s/PBM/tweets","defaultTab":"tweets","newsList":[{"id":"2604111641","title":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 09:35 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2604111641","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604111641?lang=en_us&edition=fundamental","pubTime":"2026-01-20 22:35","pubTimestamp":1768919732,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 09:35 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nAQN2LID6O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2604118832","title":"Psyence BioMed Postpones Planned Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2604118832","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604118832?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:19","pubTimestamp":1768911586,"startTime":"0","endTime":"0","summary":"Psyence Biomedical Ltd. has postponed the effective date of its previously announced 1-for-6.25 reverse stock split. The company's Board of Directors will determine a new date for the share consolidation, and the stock will continue to trade on the Nasdaq Capital Market under the ticker symbol \"PBM\" until further notice.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via GlobeNewswire  on January 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL74cn1S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0314104364.USD","SG9999014013.SGD","BK4585","LU2210150020.SGD","SG9999014005.SGD","SG9999014021.USD","LU2210149790.SGD","BK4112","IE00BKPKM429.USD","PBM","SG9999014039.USD","NDAQ","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4139","LU2095319765.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2604902031","title":"Psyence Biomed Announces Postponement of Previously Announced Reverse Stock Split Effective Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2604902031","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604902031?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:19","pubTimestamp":1768911581,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nTUA3XMQJK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2604910323","title":"Psyence Biomedical Ltd trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2604910323","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604910323?lang=en_us&edition=fundamental","pubTime":"2026-01-17 08:50","pubTimestamp":1768611043,"startTime":"0","endTime":"0","summary":"19:50 EST Psyence Biomedical (PBM) Ltd trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/psyence-biomedical-ltd-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/psyence-biomedical-ltd-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2604170199","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:50 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2604170199","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604170199?lang=en_us&edition=fundamental","pubTime":"2026-01-17 08:50","pubTimestamp":1768611000,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:50 PM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260117:nAQN2LI4OD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2603623802","title":"Psyence Biomed Announces Effective Date for 1-for-6.25 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2603623802","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603623802?lang=en_us&edition=fundamental","pubTime":"2026-01-15 08:00","pubTimestamp":1768435200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nTUA9YGDYD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PBM","BK4139"],"gpt_icon":0},{"id":"2603642623","title":"Psyence BioMed Enacts 1-for-6.25 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2603642623","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603642623?lang=en_us&edition=fundamental","pubTime":"2026-01-15 05:30","pubTimestamp":1768426258,"startTime":"0","endTime":"0","summary":"Psyence Biomedical Ltd. has announced a 1-for-6.25 reverse stock split of its issued and outstanding common shares, following a Board decision on December 4, 2025. The consolidation affects all shareholders uniformly, with fractional shares rounded according to standard procedures. Continental Stock Transfer & Trust Company is serving as the exchange and transfer agent for the process.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 14, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL3K9gzZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2602854812","title":"BRIEF-Psyence Biomed Approves 2026 Financial Strategy, Board Authorizes Share Buyback On Value Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2602854812","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602854812?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:33","pubTimestamp":1768224783,"startTime":"0","endTime":"0","summary":"BRIEF-Psyence Biomed Approves 2026 Financial Strategy, Board Authorizes Share Buyback On Value OpportunityJan 12 (Reuters) - Psyence Biomedical Ltd PBM.O:PSYENCE BIOMED APPROVES 2026 FINANCIAL STRATEG","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA2TMCPT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBM","BK4139"],"gpt_icon":0},{"id":"2602318625","title":"Psyence Biomedical Ltd. publishes MD&A report for year ended March 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2602318625","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602318625?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:08","pubTimestamp":1767906499,"startTime":"0","endTime":"0","summary":"Psyence Biomedical Ltd., a vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics, provided a business update in its latest Management’s Discussion and Analysis. The company highlighted its position as the first life sciences biotechnology company focused on developing nature-derived psilocybin and ibogaine-based medicines to be listed on Nasdaq. Psyence Biomedical remains dedicated to addressing unmet mental health needs, particularly in palliative care, and continues to advance its evidence-based approach for the development of safe psychedelic medicines. The full report can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL40PlMx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2601882220","title":"Psyence BioMed Appoints Graham Patrick to Board as Christopher Bull Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2601882220","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601882220?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:15","pubTimestamp":1767622510,"startTime":"0","endTime":"0","summary":"Psyence Biomedical Ltd. announced that Christopher Bull has resigned from its Board of Directors, effective December 1, 2025. Graham Patrick has been appointed to fill the resulting vacancy on the board.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via GlobeNewswire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL1YYmzg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014013.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014021.USD","PBM","IE00BKPKM429.USD","NDAQ","LU0314104364.USD","SG9999014039.USD","BK4588","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014005.SGD","BK4585","BK4139","BK4112"],"gpt_icon":0},{"id":"2601265882","title":"Press Release: Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2601265882","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601265882?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:15","pubTimestamp":1767622500,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan. 05, 2026  -- Psyence Biomedical Ltd.  , a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced a significant scientific and manufacturing achievement.\"The successful production of GMP-compliant Ibogaine HCl represents an important advancement for Psyence BioMed and our vertically integrated strategy,\" said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed. \"This achievement strengthens our manufacturing and quality capabilities and supports our long-term objective of advancing nature-derived psychedelic compounds through responsible, regulated development pathways.\". Psyence Biomedical Ltd.  is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived  psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We a","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM","NQmain"],"gpt_icon":0},{"id":"2592987061","title":"Correction: Investors Hope for Rate Cut Following Subdued Inflation as US Futures Mixed in Friday's Premarket Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2592987061","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592987061?lang=en_us&edition=fundamental","pubTime":"2025-12-19 22:49","pubTimestamp":1766155771,"startTime":"0","endTime":"0","summary":"(Corrects the third paragraph to note the personal income and outlays report being rescheduled.)US stock futures were mixed in Friday's premarket session, with investors hopeful of a federal rate cut ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a9f9ae861e0d5137ca1db9f83a4575ef","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVIW.SI",".DJI","BK4585","SQQQ","BK4007",".SPX","BK4116","WYFI","MYMmain","UDOW","MNQmain","DJX","QLD","BK4211","QID","MGRT","USJW.SI","DXD","DOG","DDM","TQQQ","TSYW.SI","YCBD","VMAR","BK4547","HOPE","BK4190",".IXIC","SAVA","SDOW","PSQ","USAW.SI","ISBC","NQmain","BK4139","BK4588","PBM"],"gpt_icon":1},{"id":"2592816923","title":"Psyence BioMed Wins Ethics Approval for PsyLabs Psilocybin in Phase IIb Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592816923","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592816923?lang=en_us&edition=fundamental","pubTime":"2025-12-19 20:00","pubTimestamp":1766145611,"startTime":"0","endTime":"0","summary":"Psyence Biomedical Ltd. has received formal approval from the Bellberry Human Research Ethics Committee  for the use of PsyLabs' psilocybin product  in its ongoing Phase IIb clinical trial. This approval allows Psyence BioMed to utilize PsyLabs' nature-derived, GMP-compliant psilocybin as the investigational product in a double-blind, randomized, low-dose comparator-controlled study evaluating psilocybin-assisted psychotherapy for Adjustment Disorder in cancer patients. The authorization applies to all participating study sites, with additional sites planned to accelerate patient recruitment and advance the trial. No other organizations are mentioned as recipients of this approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL9bt77k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","LU2210149790.SGD","SG9999014021.USD","SG9999014039.USD","IE00BKPKM429.USD","LU2210150020.SGD","BK4112","PBM","IE00BGHQF748.EUR","BK4588","NDAQ","SG9999014005.SGD","IE00B64PRP62.GBP","LU2095319765.USD","BK4139","LU0314104364.USD","SG9999014013.SGD"],"gpt_icon":0},{"id":"2592716948","title":"Psyence Biomed Announces Approval for Use of Psylabs’ Psilocybin Product in Phase Iib Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592716948","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592716948?lang=en_us&edition=fundamental","pubTime":"2025-12-19 20:00","pubTimestamp":1766145600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA9TGDQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2592206169","title":"Psyence Biomedical Ltd: Study Remains on Track to Deliver Top-Line Results in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2592206169","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592206169?lang=en_us&edition=fundamental","pubTime":"2025-12-19 20:00","pubTimestamp":1766145600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA9TGDQL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2592674479","title":"PBM Polytex Sells Land in Nagpur, India","url":"https://stock-news.laohu8.com/highlight/detail?id=2592674479","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592674479?lang=en_us&edition=fundamental","pubTime":"2025-12-17 16:13","pubTimestamp":1765959211,"startTime":"0","endTime":"0","summary":"PBM Polytex (BOM:514087) has sold land in the Nagpur district of Maharashtra, India, for 62.2 million Indian rupees, according to a BSE filing on Wednesday.The yarn manufacturer entered into the sale agreement with Luvkush Corp. on Dec. 12.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MNDmain","BK4139","PBM"],"gpt_icon":0},{"id":"2590343284","title":"Psyence BioMed Reports Phase IIb Trial Progress and Strengthened Cash Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2590343284","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590343284?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:02","pubTimestamp":1765281741,"startTime":"0","endTime":"0","summary":"Psyence Biomedical Ltd. announced a business update summarizing its achievements for 2025 and outlining its strategic vision for 2026. The company reported the recruitment and dosing of the first patients in a Phase IIb clinical trial evaluating psilocybin-assisted psychotherapy for the treatment of Adjustment Disorder in palliative care, with multiple patients dosed at several Australian sites. Psyence BioMed strengthened its manufacturing capabilities through a follow-on investment in PsyLabs, securing GMP-compliant psilocybin and ibogaine supply, and announced a breakthrough in high purity ibogaine production. The company ended 2025 debt-free, with over USD $9 million in cash reserves. Looking ahead to 2026, Psyence BioMed plans to accelerate clinical trial enrollment, expand its manufacturing footprint, pursue additional longevity-focused indications, and explore strategic partnerships.Disclaimer: This news brief was created by Public Technologies  using generative artificial intel","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL7ZRtgy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014013.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014021.USD","PBM","IE00BKPKM429.USD","NDAQ","LU0314104364.USD","SG9999014039.USD","BK4588","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014005.SGD","BK4585","BK4139","BK4112"],"gpt_icon":0},{"id":"2586992420","title":"Psyence BioMed Launches Psilocybin Longevity Research Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2586992420","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586992420?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:11","pubTimestamp":1764072701,"startTime":"0","endTime":"0","summary":"Psyence Biomedical Ltd. has announced the launch of a pioneering psilocybin longevity research program in collaboration with researchers in South Africa. The initiative aims to investigate the potential impact of psilocybin on biological markers associated with aging, including cellular stress, inflammation, mitochondrial function, and behavioral indicators of healthspan and lifespan. The research, led by Dr. Tanya Calvey, is currently in the project commencement phase, with accelerated progress expected early next year following ethics approval. No scientific results have been presented yet; the study is in its early stages.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to g","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL1svZPY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2585299129","title":"Psyence BioMed Takes Minority Stake in PsyLabs to Boost African Ibogaine Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2585299129","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585299129?lang=en_us&edition=fundamental","pubTime":"2025-11-22 06:18","pubTimestamp":1763763527,"startTime":"0","endTime":"0","summary":"Psyence BioMed, a biopharmaceutical company focused on nature-derived psilocybin and ibogaine therapies, has made a strategic equity investment in PsyLabs. This transaction establishes Psyence BioMed as the only publicly listed psychedelics company with active operations and manufacturing capabilities based in Africa, the original source of ibogaine. The investment strengthens Psyence BioMed's supply chain and provides shareholders with early access to pipeline products, intellectual property development, and supply channels as global demand for psychedelic active pharmaceutical ingredients  increases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL6HcXWw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2584690998","title":"WellsCare Partners with SolnanoMed to Launch IASO and IASO Ultra in Thailand","url":"https://stock-news.laohu8.com/highlight/detail?id=2584690998","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584690998?lang=en_us&edition=fundamental","pubTime":"2025-11-17 10:00","pubTimestamp":1763344800,"startTime":"0","endTime":"0","summary":"Partnership to Bring Innovative Wearable Cold-Laser Therapy to One of Southeast Asia's Fastest-Growing Healthcare Markets  SEOUL, South Korea, Nov. 17, 2025 /PRNewswire/ -- WellsCare Inc., a leading South Korean med-tech innovator in wearable cold-laser therapy, today announced that it has signed a supply agreement with SolnanoMed Co., Ltd., one of Thailand's most respected medical device distributors. The agreement follows WellsCare's recent FDA Thai approval for its flagship product, IASO Coldlaser — advanced photobiomodulation  therapy device designed for effective, drug-free pain management.IASO products come with convenient wearable bands and hydrocolloid adhesive patches so that you can wear the device hands-free, anywhere you experience pain.Through this partnership, SolnanoMed will serve as WellsCare's exclusive distributor in Thailand, covering hospitals, clinics, and retail channels nationwide. Together, the two companies aim to make hospital-grade pain-relief technology acce","market":"other","thumbnail":"https://mma.prnewswire.com/media/2822259/WellsCare__co_ltd_Photos_attached_to_press_releases_20251111.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2822259/WellsCare__co_ltd_Photos_attached_to_press_releases_20251111.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/wellscare-partners-with-solnanomed-to-launch-iaso-and-iaso-ultra-in-thailand-302614265.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBM","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pacificbooker.bc.ca","stockEarnings":[{"period":"1week","weight":-0.863},{"period":"1month","weight":-0.8928},{"period":"3month","weight":-0.967},{"period":"6month","weight":-0.9893},{"period":"1year","weight":-0.9925},{"period":"ytd","weight":-0.8577}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0044},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.068},{"period":"1year","weight":0.1339},{"period":"ytd","weight":-0.0064}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.379517},{"month":2,"riseRate":0.5,"avgChangeRate":-0.224323},{"month":3,"riseRate":0.75,"avgChangeRate":0.142672},{"month":4,"riseRate":0.5,"avgChangeRate":-0.110088},{"month":5,"riseRate":0.5,"avgChangeRate":0.047065},{"month":6,"riseRate":0.75,"avgChangeRate":-0.123687},{"month":7,"riseRate":0.75,"avgChangeRate":0.230875},{"month":8,"riseRate":0.5,"avgChangeRate":-0.181154},{"month":9,"riseRate":0.75,"avgChangeRate":-0.153581},{"month":10,"riseRate":0.25,"avgChangeRate":-0.079288},{"month":11,"riseRate":0.25,"avgChangeRate":-0.211015},{"month":12,"riseRate":0.25,"avgChangeRate":-0.267978}],"exchange":"NASDAQ","name":"Psyence Biomedical Ltd","nameEN":"Psyence Biomedical Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Psyence Biomedical Ltd(PBM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Psyence Biomedical Ltd(PBM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Psyence Biomedical Ltd,PBM,Psyence Biomedical Ltd股票,Psyence Biomedical Ltd股票老虎,Psyence Biomedical Ltd股票老虎国际,Psyence Biomedical Ltd行情,Psyence Biomedical Ltd股票行情,Psyence Biomedical Ltd股价,Psyence Biomedical Ltd股市,Psyence Biomedical Ltd股票价格,Psyence Biomedical Ltd股票交易,Psyence Biomedical Ltd股票购买,Psyence Biomedical Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Psyence Biomedical Ltd(PBM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Psyence Biomedical Ltd(PBM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}